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Background: Obstructive sleep apnea (OSA) increases the risk of cardiovascular disease (CVD)
and has been reported to be associated with chronic kidney disease (CKD). Recent studies have
demonstrated that cystatin C is a prognostic biomarker of the risk of death and CVD even in
patients without established CKD.
Methods: In a cross-sectional study, we enrolled 267 consecutive OSA patients without CKD
who had an apnea-hypopnea index (AHI)  5 events per hour in overnight polysomnography.
CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 ac-
cording to the modification of diet in renal disease (MDRD) equation (modified for Japanese).
Serum cystatin C levels were measured in all patients.
Results: Cystatin C was significantly correlated with age (r Z 0.37), body mass index (BMI)
(rZ 0.12), AHI (rZ 0.17), C-reactive protein (CRP) (rZ 0.12), and Brachial-ankle pulse wave
velocity (r Z 0.18). Logistic regression analysis demonstrated that severe OSA defined by an
AHI  30 events per hour was an independent variable for the highest quartiles of serum cy-
statin C levels (0.88 mg/L) (OR: 2.04, 95% CI: 1.04e4.01, P Z 0.04) even after adjustment
for age, BMI  25, hypertension, and diabetes mellitus.
Conclusions: This study indicates that severe OSA independently increases serum cystatin C
levels in patients without CKD. Cystatin C is considered to be a biomarker that reflects both
clinically latent renal dysfunction and cardiovascular risk that are influenced by OSA.
ª 2010 Elsevier Ltd. All rights reserved.3342 6111; fax: þ81 3 3342 4820.
net.ne.jp (Y. Takata).
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Previous studies1e4 have demonstrated that chronic kidney
disease (CKD), defined by a glomerular filtration rate
(GFR) < 60 mL/min/1.73 m2, is an independent factor that
increases the risks of cardiovascular disease (CVD) death.
Furthermore, a recent study5 has reported that renal func-
tion impairment becomes a risk of CVD also at an early stage
where renal function impairment has not become CKD
(clinically latent CKD). Therefore, emphasis has been placed
on the need to take preventive measures at an earlier stage.
On the other hand, obstructive sleep apnea (OSA) is
a disorder that shows repeated episodes of frequent apnea
and hypopnea due to upper airway obstruction during
sleep. Severe hypoxemia and arousals during sleep enhance
the activity of sympathetic nerves and are well known to
become risk factors for CVD, e.g., hypertension, heart
failure, and stroke.6,7 Recent studies8,9 have reported that
patients with sleep disordered breathing (SDB) present
a high prevalence of CKD and that patients with early CKD
exhibit a high incidence of SDB; therefore, the association
between the two clinical conditions has drawn attention.
We consider that OSA is more certainly involved in the
progression of renal function impairment to CKD if OSA also
influences clinical conditions that are found at a clinically
latent stage.
Cystatin C, a 13-kD protein and a member of a family of
competitive inhibitors of lysosomal cystein protease, is less
likely to be influenced by extrarenal factors, e.g., muscle
mass, age, and gender, because it is constantly produced in
a given amount by nucleated cells in organs and tissues of
whole body. Cystatin C is filtrated by glomeruli, is reab-
sorbed (99%) in the proximal convoluted tubules, is
catabolized, and is not recirculated into blood. Therefore,
cystatin C is a biomarker that sensitively reflects the
impairment of glomerular filtration function. Especially,
cystatin C has an excellent ability to detect clinically latent
CKD, and elevated serum cystatin C level has been reported
to reflect cardiovascular mortality.5
The objective of the present study was to investigate
whether OSA influences renal function in patients with
clinically latent CKD through cystatin C, a biomarker that
more sensitively reflects renal function than conventional
biomarkers.
Materials and methods
Patients
The present study was conducted in 345 consecutive Japa-
nese adult patients who had been medically examined in
Sleep Disorder Division, Department of Cardiology at Tokyo
Medical University Hospital due to suspected SDB in an
abbreviated testing and who underwent polysomnography
(PSG) between September 1, 2006 and April 30, 2008. The
following patients were excluded from the study: patients
with predominance of central sleep apnea or Cheyne-Stokes
respiration; patients on hemodialysis; and patients who
were already treated for OSA with continuous positive
airway pressure or an oral appliance. Among them, 82
patients diagnosed with CKD based on an estimated GFR(eGFR) < 60 mL/min/1.73 m2 were excluded. Eventually,
267 patients (233 males and 34 females; mean age  SD,
51  14 years) diagnosed with OSA based on an AHI  5
events/h were analyzed.
The present study was conducted in compliance with
the Declaration of Helsinki and in accordance with "A
guideline for the protection of patient privacy in medical
papers including case reports" after acquisition of the
approval by the ethical review board at Tokyo Medical
University Hospital. Written informed consent was obtained
from all patients before the conduct of any study-related
procedures.
Overnight PSG
Overnight, fully attended PSG monitoring was performed
with the Alice 4 Sleep System (Respironics, Murrysville, PA,
USA) at our sleep laboratories. Sleep stages were monitored
by electroencephalography, electrooculography, and elec-
tromyography according to the standard criteria,10 and
arousals were defined according to the standard criteria of
the American Academy of Sleep Medicine.11 Oronasal airflow
was measured with a thermistor, thoracoabdominal move-
ments were monitored with a strain gauge, and the oxyhe-
moglobin saturation in the blood was monitored by pulse
oximetry. Respiratory events were scored manually. Apnea
was defined as the cessation of oronasal airflow for 10 s or
more, and hypopnea was defined as a 50% or greater
decrease in oronasal airflow lasting for more than 10 s
associated with a 3% or greater decrease in arterial oxygen
saturation compared to the baseline level. The AHI was
calculated as the total number of apnea and hypopnea
episodes per hour of sleep. The patient was classified as
having OSA when the obstructive component was dominant
and the AHI was 5 events/h or more. The severity of OSAwas
classified according the American Academy of Sleep Medi-
cine criteria.12 Moreover, a 3% or greater decrease in arterial
oxygen saturation was defined by the oxygen desaturation
index (ODI) 3%.
Data collection
In the next morning of PSG, venous blood was collected from
the patient in the supine position at rest during fasting to
measure the serum levels of the following substances: cys-
tatin C, high-sensitivity C-reactive protein (hsCRP), creati-
nine, total cholesterol, low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C),
triglyceride (TG), and glycosylated hemoglobin. Centrifuged
serum (3000 rpm, 10 min) cryopreserved at 20 C was used
to measure cystatin C and hsCRP with a BN II nephelometer
(Dade Berhring, Deerfield, IL, USA). Before the conduct of
PSG, a volume-plethysmographic apparatus (Form/ABI,
OMRON Colin Co., Ltd., Kyoto, Japan) was used to measure
blood pressures and brachial-ankle pulse wave velocity
(baPWV). Hypertension was defined by a systolic blood
pressure 140mmHg, a diastolic blood pressure 90mmHg,
or treated previously. Diabetes mellitus was defined by
fasting plasma glucose  126 mg/dL, postprandial casual
plasma glucose  200 mg/dL, or treated previously. Dysli-
pidemia was defined by LDL-C 140 mg/dL, HDL-C< 40 mg/
dL, TG  150 mg/dL, or treated previously.
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Serum creatinine and age were used to calculate eGFR
(mL/min/1.73 m2). The following estimation formula
modified for Japanese with respect to the modification of
diet in renal disease (MDRD)13,14 was used to calculate
eGRF: eGFR Z 0.808  175  Cr1.154  Age0.203 (0.742
for females). CKD was diagnosed when obtaining an
eGFR < 60 mL/min/1.73 m2.
Statistical analysis
Measurement values are expressed asmeanSD. Spearman’s
test was performed to analyze the correlations between
serumcystatin C levels and cardiovascular risk variables (AHI,
age, BMI, hsCRP, and baPWV). Furthermore, the one-way
analysis of varianceon thequartiles of serumcystatin C levels
was performed to compare variables in each group. The
univariate and multivariate logistic regression analyses were
performed to examine independent factors that specify Q4,
the highest quartile group of serum cystatin C levels. A value
of P < 0.05 was considered to be statistically significant. All
analyses were performed using the SPSS-PC þ computer
program (Version 11.0; SPSS, Chicago, IL, USA).
Results
Patient characteristics
The mean age  SD of 267 patients was 51  14 years. Males
accounted for 81%, the mean AHI was 37.9  23.5 events/h,
the mean serum cystatin C level was 0.82  0.13 mg/L, and
eGFR was 85.1  16.6 mL/min/1.73 m2. Hypertension,
diabetes mellitus, and dyslipidemia were found in 57.7%,
24.0%, and 59.9% of patients, respectively (Table 1).
Cystatin C and cardiovascular risk variables
Correlations between serum cystatin C levels and cardio-
vascular risk variables are shown in Fig. 1 (A) to (E). Serum
cystatin C levels showed significant correlations with all ofTable 1 Characteristics of 267 patients.
Age (years)
Gender (men/women)
BMI (kg/m2)
Hypertension (%)
Diabetes mellitus (%)
Dyslipidemia (%)
eGFR (mL/min/1.73m2)
hsCRP (mg/dL)
baPWV (cm/sec)
Systolic BP (mmHg)
Diastolic BP (mmHg)
AHI (events/h)
Arousal index (events/h)
Lowest SpO2 (%)
Values are expressed as mean  SD. AHI: apnea-hypopnea index; BM
hsCRP: high-sensitivity C-reactive protein; baPWV: brachial-ankle pulthe following variables: AHI (rZ 0.17); age (rZ 0.37); BMI
(r Z 0.12); hsCRP (r Z 0.12); and baPWV (r Z 0.18).
The quartile groups of serum cystatin C levels Q1 to Q4
(Q1:<0.74mg/L; Q2: 0.74e0.80mg/L; Q3: 0.81e0.87mg/L;
andQ4:0.88mg/L)were calculated, and themeans SD of
the variables in each group are shown (Table 2). The vari-
ables, which showed statistically significantly high values in
Q4dthe highest quartile group of serum cystatin C levelsd,
were age, AHI, hsCRP, and baPWV.
Logistic regression analyses
The univariate analysis of factors that specify Q4 was per-
formed. The independent factors that specified Q4 were as
follows: severe OSA (AHI:  30 events/h); age; obesity (BMI:
 25 kg/m2); hsCRP; baPWV; presence of hypertension; and
presence of diabetes mellitus. The multivariate analysis
revealed that severe OSA was a potent factor (OR, 2.04; 95%
CI, 1.04e4.01; PZ 0.04) which specified Q4 independently
from age and obesity (Table 3).
Discussion
The present cross-sectional study indicated that high serum
levels of cystatin C were found in correlation with the
severity of OSA in a group of patients who had clinically
latent CKD and who were diagnosed with OSA. Further-
more, severe OSA was an independent factor that specifies
Q4dthe highest quartile group of serum cystatin C levels.
These results suggest that OSA also deteriorates renal
function in patients with clinically latent CKD.
Serum creatinine, which has widely been used as a vari-
able for renal function, is affected by extrarenal factors,
e.g., gender, age, and muscle mass. Hence, serum creati-
nine is occasionally underestimated or overestimated than
actual renal function. On the other hand, cystatin C is
a biomarker that is less affected by extrarenal factors, is
stable, requires no urine accumulation, and reflects renal
function more sensitively than serum creatinine.15e17
Furthermore, cystatin C is capable of detecting clinically
latent CKD as suggested by our study.51  14
233/34
26.3  4.7
57.7
24.0
59.9
85.1  16.6
0.15  0.22
1458  261
126  15
75  10
37.9  23.5
39.4  19.9
80.7  8.4
I: body mass index; eGFR: estimated glomerular filtration rate;
se wave velocity.
Figure 1 Correlations between serum cystatin C levels and cardiovascular risk factor variables. Serum cystatin C levels showed
significant correlations with all of the following variables: Panel (A) apnea-hypopnea index (r Z 0.17, P Z 0.007); Panel (B) age
(r Z 0.37, P < 0.001); Panel (C) body mass index (r Z 0.12, P Z 0.045); Panel (D) high-sensitivity C-reactive protein (r Z 0.12,
P Z 0.045); and Panel (E) brachial-ankle pulse wave velocity (r Z 0.18, P Z 0.003). r denotes Pearson’s correlation coefficient.
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tive variable for renal function but also attracts attention
because of its independent relationship fromCVD. In a cohort
study in elderly patients to compare serum levels of creati-
nine and cystatin C as predictive factors for cardiovascular
death and all-cause death, elevated serum cystatin C level
was an independent predictive factor for CVD. On the other
hand, creatinine showed no such relationship.18 In addition,
990 patients with coronary artery disease were analyzed for
total mortality, CVD event, and onset of heart failure.19
Consequently, elevated serum cystatin C level was an inde-
pendent predictive factor for all of them. The tendency was
observed regardless of the presence or absence of decreased
eGFR or of urinary minute albumin. Namely, cystatin C has
been suggested to be a biomarker that reflects not only GFRbut also the increased risk of CVD through some mechanism
that differs from renal function impairment.
Recent studies have investigated the relationship
between cystatin C and cardiovascular events in patients
with coronary artery disease and with normal or mildly
reduced kidney function. Consequently, the highest quar-
tile group of cystatin C remained to be an independent
factor for CVD death event after correction for classical risk
factors (BMI, smoking history, diabetes mellitus, dyslipide-
mia, LDL/HDL ratio, and CRP) and for NT-proBNP.5
In thepresent study that did not include patientswithCKD,
elevated serum cystatin C level was correlated with CRP
and baPWVdknown predictive factors for cardiovascular
events. CRP is knownasan inflammationmarker that is closely
associated with cardiovascular events.20 Furthermore, many
Table 2 Characteristics of 267 participants by quartile of cystatin C.
Quartile Q1 Q2 Q3 Q4
Cystatin C (mg/L) < 0.74 0.74e0.80 0.81e0.87  0.88
n 64 69 64 70
Age (years) 46  13 48  13 52  14*,# 58  14*,#
Men (%) 85.9 85.5 89.0 88.6
Hypertension (%) 57.8 50.7 52.4 69.6
Diabetes mellitus (%) 18.8 21.7 21.9 32.9
AHI (events/h) 33.4  25.7 36.3  23.7 37.7  22.2 43.9  23.5*
BMI (kg/m2) 25.7  4.3 25.9  4.8 25.9  5.0 27.5  4.7
eGFR (mL/min/1.73 m2) 98.0  18.2 86.2  12.3* 80.6  15.1*,# 76.2  12.3*,#,{
hsCRP (mg/dL) 0.14  0.29 0.10  0.15 0.21  0.35 0.25  0.36 #
Systolic BP (mmHg) 127  14 125  14 124  15 126  16
Diastolic BP (mmHg) 75  10 76  11 74  10 77  10
TG (mg/dL) 151  69 171  128 166  90 174  102
LDL (mg/dL) 121  34 123  32 120  30 123  33
baPWV (cm/sec) 1432  257 1421  220 1426  244 1549  300*,#,{
Values are expressed as mean  SD. P < 0.05 against Q1*, Q2#, Q3{. AHI: apnea-hypopnea index; BMI: body mass index; eGFR: estimated
glomerular filtration rate; hsCRP: high-sensitivity C-reactive protein; BP: blood pressure, TG: triglyceride; LDL: low-density lipoprotein
cholesterol; baPWV: brachial-ankle pulse wave velocity.
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the severity of coronary artery disease and PWV.21,22 Elevated
PWV has been shown to be a predictive factor for the onse-
t of CVD.23 In the present study, cystatin C is not only sensi-
tively reflected renal function but also is a biomarker that
can potentially predict cardiovascular events. Therefore,
patients with elevated serum cystatin C level may be
considered at high risk of presenting the onset or progression
of both CKD and CVD. This fact indicates the need for earlier
therapeutic interventions also in patients with clinically
latent CKD that cannot be detected when investigated based
on eGFR.
Previous studies have shown that OSA is an independent
factor which increases the risk of CVD and that patients with
severe OSA are at high risk of cardiovascular death.24e28 A
recent study reported that patients with SDB are highly
frequently complicated by CKD.8 By contraries, patients with
early CKD demonstrated an increased risk of sleep apnea.29
The kidney is an organ that is known for its very high
sensitivity for hypoxemia and for the strong predominance of
autonomic nerves. The admissible mechanisms by which OSA
induces CKD include intermittent hypoxemia during sleep,
activation of sympathetic nerves by sleep fragmentation,
glomerular hypertension possibly caused by an increase in
blood pressure, and vascular endothelial damage due toTable 3 Univariate and multivariate analyses using binary logistic
Univariate OR (95% CI) P
AHI:  30 2.940 (1.620e5.338) <
Age 1.052 (1.029e1.076) <
BMI:  25 1.950 (1.093e3.476)
hsCRP 1.809 (1.067e3.066)
baPWV 1.002 (1.001e1.003)
Hypertension 1.981 (1.104e3.066)
Diabetes mellitus 1.862 (1.016e3.413)
AHI: apnea-hypopnea index; BMI: body mass index; hsCRP: high-se
velocity; n.s.: not significant.oxidative stress or inflammation; however, any details have
not been elucidated.29 In addition, OSA is fully predicted to
possibly lead to the deterioration of renal function through
the constituent factors of obesity and metabolic syndrome
that are complicated with OSA.30,31
Canales et al.9 have shown the relationship between SDB
and reduced renal function in the elderly. Our study supports
their study. However, our patients had mean ages of 51  14
years; therefore, our study indicated the possible involve-
ment of OSA in the onset and/or progression of CKD in a wide
age range of patients including not only the elderly but also
young adults. Simultaneously, we successfully demonstrated
that OSA is probably associated with the onset of both renal
function impairment and CVD because cystatin C was asso-
ciated with factors that specify cardiovascular events, e.g.,
CRP and PWV.
Our study has several limitations. First, it is a cross-
sectional study. Therefore, long-term follow-up is required
to verify whether patients with elevated serum cystatin C
level obviously develop renal function impairment or
experience the onset of cardiovascular events at a high
rate. Second, further study will be required to investigate
whether therapeutic interventions, e.g., CPAP for OSA,
make it possible to suppress the onset and/or progression of
renal function impairment. Third, GFR was not measuredregression for determining the highest quartile of cystatin C.
value Multivariate OR (95% CI) P value
0.001 2.038 (1.036e4.010) 0.04
0.001 1.042 (1.013e1.073) 0.005
0.024 1.995 (1.017e3.912) 0.04
0.028 e n.s.
0.001 e n.s.
0.022 e n.s.
0.044 e n.s.
nsitivity C-reactive protein; baPWV: brachial-ankle pulse wave
648 K. Kato et al.directly because of clinical difficulty but was calculated
according to a formula modified to estimate GFR in the
Japanese population. Fourth, our study probably included
patients diagnosed with CKD even despite having an
eGFR  60 mL/min/1.73 m2 in analyzed patients because
proteins and albumin in urine had not been measured.
In conclusion, severe OSA is an independent factor that
elevates cystatin C, thus probably indicating its involve-
ment in the onset and/or progression of clinically latent
CKD. Namely, OSA is a potential risk factor of CKD.
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